A central paradox in transforming growth factor beta (TGF-?) biology is how the same growth factor can induce such divergent responses as growth stimulation (i.e., mesenchymal cells) and growth inhibition (i.e., epithelial cells)? Considering the pivotal role TGF-? has in a number of normal and pathological conditions, addressing that issue is fundamental if we hope to develop specific intervention strategies. To that end, we have been investigating the general hypothesis that TGF-? stimulates cell type-specific signaling pathways as a means to regulate these phenotypes. One target with a critical role in coordinating the profibrogenic (i.e., mesenchymal), in contrast to the growth inhibitory (i.e., epithelial), cellular response to TGF-? is PI3K. During the previous funding cycle we have shown that PI3K represents a branchpoint in Smad-independent TGF-? signaling such that one arm leads to activation of Pak2 and c-Abl, while the other is coupled to Akt and mTOR. As this former finding has led to a multi-center Phase II clinical trial testing the efficacy of imatinib mesylate vs. placebo in the treatment of idiopathic pulmonary fibrosis, we will extend these concepts in the competing renewal using a variety of biochemical, biological, and morphologic approaches. First, we will determine the mechanism(s) by which TGF-? activation of mTOR stimulates stromal cell proliferation. It is proposed that greater efficacy and lower toxicity can be obtained in models of TGF-? driven tissue fibrosis by inhibiting both Pak2/c-Abl and Akt/mTOR branches downstream of PI3K. Second, the role of guanine nucleotide exchange factor (GEF) phosphorylation and receptor association in directing TGF-? target specificity and receptor activation will be defined. Third, a candidate protein has been identified which regulates fibroblast-specific TGF-? signaling, experiments are proposed to determine the mechanism(s) which prevents or promotes activation of these pathways in epithelial and mesenchymal cells, respectively. Answers to these questions are critical if the processes mediating cell type-specific TGF-? signaling are to be elucidated. ? Relevance to public health (lay language): TGF-? is a protein which can be either helpful or harmful to human health. While its ability to stimulate cell growth is important for normal wound healing, when unchecked the function of many organs can be disrupted by scar (i.e., fibrosis) formation. The proposed studies will identify/characterize targets which can be used to either increase or decrease this response. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM054200-13
Application #
7391782
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Anderson, Richard A
Project Start
1996-05-01
Project End
2011-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
13
Fiscal Year
2008
Total Cost
$326,340
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Yang, Binxia; Kilari, Sreenivasulu; Brahmbhatt, Akshaar et al. (2017) CorMatrix Wrapped Around the Adventitia of the Arteriovenous Fistula Outflow Vein Attenuates Venous Neointimal Hyperplasia. Sci Rep 7:14298
Yin, Xueqian; Kang, Jeong-Han; Andrianifahanana, Mahefatiana et al. (2017) Basolateral delivery of the type I transforming growth factor beta receptor is mediated by a dominant-acting cytoplasmic motif. Mol Biol Cell 28:2701-2711
Kang, Jeong-Han; Jung, Mi-Yeon; Yin, Xueqian et al. (2017) Cell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-? signaling. J Clin Invest 127:2541-2554
Yang, Binxia; Brahmbhatt, Akshaar; Nieves Torres, Evelyn et al. (2016) Tracking and Therapeutic Value of Human Adipose Tissue-derived Mesenchymal Stem Cell Transplantation in Reducing Venous Neointimal Hyperplasia Associated with Arteriovenous Fistula. Radiology 279:513-22
Janardhanan, Rajiv; Yang, Binxia; Kilari, Sreenivasulu et al. (2016) The Role of Repeat Administration of Adventitial Delivery of Lentivirus-shRNA-Vegf-A in Arteriovenous Fistula to Prevent Venous Stenosis Formation. J Vasc Interv Radiol 27:576-83
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Andrianifahanana, Mahefatiana; Hernandez, Danielle M; Yin, Xueqian et al. (2016) Profibrotic up-regulation of glucose transporter 1 by TGF-? involves activation of MEK and mammalian target of rapamycin complex 2 pathways. FASEB J 30:3733-3744
Wilkes, Mark C; Repellin, Claire E; Kang, Jeong-Han et al. (2015) Sorting nexin 9 differentiates ligand-activated Smad3 from Smad2 for nuclear import and transforming growth factor ? signaling. Mol Biol Cell 26:3879-91
Nallet-Staub, Flore; Yin, Xueqian; Gilbert, Cristèle et al. (2015) Cell density sensing alters TGF-? signaling in a cell-type-specific manner, independent from Hippo pathway activation. Dev Cell 32:640-51

Showing the most recent 10 out of 46 publications